What's in Walter K. Kraft's pipeline?

Walter K. Kraft has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Walter K. Kraft's portfolio?

Top competitors by shared drug class: National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention, International Partnership for Microbicides, Inc., French National Agency for Research on AIDS and Viral Hepatitis, Germans Trias i Pujol Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/walter-k-kraft.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Walter K. Kraft — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Walter K. Kraft pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Doravirine (DOR)	Doravirine (DOR)	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase	Infectious Disease / Virology
Rifapentine (RPT)	Rifapentine (RPT)	phase 3	Rifamycin antibiotic	Bacterial RNA polymerase	Infectious Disease

Therapeutic area mix

Infectious Disease · 1
Infectious Disease / Virology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Institute of Allergy and Infectious Diseases (NIAID) · 2 shared drug classes
Centers for Disease Control and Prevention · 1 shared drug class
International Partnership for Microbicides, Inc. · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
Germans Trias i Pujol Hospital · 1 shared drug class
Institute of Tropical Medicine, Belgium · 1 shared drug class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
Bausch Health Americas, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Walter K. Kraft:

Cite this brief

Drug Landscape (2026). Walter K. Kraft — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/walter-k-kraft. Accessed 2026-05-17.